Hikma enters settlement agreement with Jazz to sell Xyrem generic

07-04-2017

Hikma enters settlement agreement with Jazz to sell Xyrem generic

mediaphotos / iStockphoto.com

Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem (sodium oxybate).


Hikma Pharmaceuticals, Jazz, Xyrem, patent, West-Ward, settlement agreement, generics, patent infringement

LSIPR